Engineering Lymph-node Targeted IL-35 to Suppress Inflammation & Autoimmune Diseases

Time: 8:50 am
day: Conference Day Two


  • Outlining challenges in production of IL-35, a strong multi-pathway anti-inflammatory cytokine
  • Utilizing computational structural analyses to identify the intracellular binding site of IL35, succeeding large-scale production by mammalian cells
  • Engineering lymph-node targeted IL-35, which achieves therapeutic effects in rheumatoid arthritis and directly suppresses activated immune cells